1-3 of 3
Merlin Efraim
Close
Sort by
Journal Articles

Updated Phase I/II Safety and Efficacy Results for Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed/Refractory Immune Thrombocytopenia

David J. Kuter, Nikolay Tzvetkov, Merlin Efraim, Zane Kaplan, Jiří Mayer, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Ross Baker, Robert J. Bird, Mamta Garg, Jaromir Gumulec, Milan Kostal, Terry Gernsheimer, Waleed Ghanima, Olga Bandman, Puneet Arora, Regan Burns, Mengjie Yao, Ahmed Daak, Timothee Sourdille, Fareha Iqbal, Dolca Thomas, Ann Neale, Nichola Cooper
Journal: Blood
Blood (2021) 138 (Supplement 1): 14.
https://doi.org/10.1182/blood-2021-145128
Published: 2021
Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-134932
Published: 2020
Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 87.
https://doi.org/10.1182/blood-2019-122336
Published: 2019